Canada Pension Plan Investment Board Invests $5.89 Million in Progyny, Inc. (NASDAQ:PGNY)

Canada Pension Plan Investment Board acquired a new stake in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 341,300 shares of the company's stock, valued at approximately $5,887,000. Canada Pension Plan Investment Board owned 0.40% of Progyny as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Progyny by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 8,692,132 shares of the company's stock worth $149,939,000 after purchasing an additional 48,271 shares during the period. Pacer Advisors Inc. lifted its position in Progyny by 47.5% during the fourth quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company's stock worth $63,414,000 after buying an additional 1,183,558 shares during the period. River Road Asset Management LLC purchased a new position in Progyny during the fourth quarter worth about $25,529,000. Fort Washington Investment Advisors Inc. OH boosted its stake in Progyny by 90.1% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock worth $25,319,000 after buying an additional 695,740 shares during the last quarter. Finally, Barclays PLC grew its holdings in Progyny by 95.7% in the 4th quarter. Barclays PLC now owns 1,382,205 shares of the company's stock valued at $23,843,000 after buying an additional 676,048 shares during the period. Institutional investors and hedge funds own 94.93% of the company's stock.

Analyst Ratings Changes

PGNY has been the topic of several recent analyst reports. BTIG Research upgraded shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective on the stock in a report on Monday, March 31st. Canaccord Genuity Group lifted their price target on shares of Progyny from $17.00 to $23.00 and gave the company a "hold" rating in a report on Friday, February 28th. JPMorgan Chase & Co. upped their price objective on Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a report on Tuesday, January 28th. Finally, Bank of America increased their target price on Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, February 11th. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $23.64.

Progyny Trading Down 0.6 %

NASDAQ:PGNY traded down $0.14 during mid-day trading on Friday, hitting $22.76. The company had a trading volume of 530,308 shares, compared to its average volume of 1,748,155. Progyny, Inc. has a 1 year low of $13.39 and a 1 year high of $33.84. The business has a fifty day simple moving average of $21.94 and a 200-day simple moving average of $19.09. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of 39.24, a PEG ratio of 2.39 and a beta of 1.33.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.